

RECEIVED  
CENTRAL FAX CENTERDEC 23, 2004  
Response to Office Action

Serial No. 09/980,516

**Amendments to the Claims:**

1. (Currently Amended) A formulation ~~for targeting an infectious agent which acquires a HLA-DR host membrane protein during its life cycle or a HLA-DR expressing host cell or both, said formulation comprising which comprises~~ a ligand capable of binding to said host membrane a HLA-DR protein, said ligand being coupled to a lipid-comprising vesicle.
2. (Currently Amended) ~~A~~The formulation according to claim 1 wherein said lipid-comprising vesicle is a liposome.
3. (Currently Amended) ~~A~~The formulation according to claim 2 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
4. (Currently Amended) ~~A~~The formulation according to claim 3, wherein said lipid component liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.
5. (Currently Amended) ~~A~~The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight ~~comprises between about 500 and 5000 daltons.~~
6. (Currently Amended) ~~A~~The formulation according to claim 3, wherein the molar ratio is 10:3.
7. (Currently Amended) ~~A~~The formulation according to claim 4, wherein said lipid component liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.

Serial No. 09/980,516

Response to Office Action

8. (Currently Amended) ~~A~~The formulation according to claim 2, wherein said ~~lipid component~~liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.
9. (Currently Amended) ~~A~~The formulation according to claim 2, wherein said ~~lipid component~~liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.
10. (Currently Amended) ~~A~~The formulation according to claim 1, wherein ~~said host membrane protein~~ further comprising an additional ligand to one or more proteins selected from a histocompatibility complex protein other than HLA-DR, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD11d (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and ~~132B~~ 2-microglobulin.
11. (Currently Amended) ~~A~~The formulation according to claim 1, wherein said ligand is an antibody molecule selected from a whole antibody and an antibody fragment.
12. (Currently Amended) ~~A~~The formulation according to claim 1, which comprises a drug effective against a disease or against the symptoms of a disease caused by ~~an~~said infectious agent.
13. (Currently Amended) ~~A~~The formulation according to claim 1, wherein said ~~host cell~~ HLA-DR protein is expressed in a lymphoid cell or a cell of the reticuloendothelial system.

Serial No. 09/980,516

Response to Office Action

14. (Currently Amended) ~~The~~A formulation according to claim 12, wherein said ~~host cell~~ HLA-DR protein is expressed in a lymphoid cell or a cell of the reticuloendothelial system.
15. (Currently Amended) ~~A~~The formulation according to claim 13, wherein said ~~infectious agent~~ HLA-DR protein is expressed in HIV.
16. (Currently Amended) ~~A~~The formulation according to claim 14, wherein said ~~infectious agent~~ HLA-DR protein is expressed in HIV.
17. (Currently Amended) ~~A~~The ~~for~~ formulation according to claim 13, wherein said ~~host membrane protein~~ ligand further comprises an additional ligand to one or more of CD4, MHC-I or CD54 proteins.
18. (Currently Amended) ~~The~~A formulation according to claim 14, wherein said ~~host membrane protein~~ further comprises an additional ligand to one or more of CD4, MHC-I or CD54 proteins.
19. (Currently Amended) ~~A~~The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, ritonavir, nelfinavir, ganciclovir, foscarnet, ribavirin, amphotericin B and nystatin A.
20. (Currently Amended) ~~A~~The formulation according to claim 1, wherein ~~said protein is HLA-DR and said ligand is an anti-Fab' antibody fragment directed against said host membrane~~ pa HLA-DR protein.
- 21 – 23. (Canceled)